This approach could potentially overcome resistance mechanisms seen with current checkpoint inhibitors. The clinical program is already well-advanced with over 1,000 patients treated and ongoing Phase 3 trials in lung cancer indications. The planned expansion into triple-negative breast cancer by year-end further broadens the market potential. BMS brings critical commercialization expertise in immuno-oncology, having pioneered several successful checkpoint inhibitors. The 50/50 profit-sharing structure is favorable for BioNTech compared to typical royalty arrangements, indicating BMS's strong confidence in the asset. Importantly, both companies retain rights to develop BNT327 in additional indications and combinations with their respective pipelines, creating multiple paths for maximizing the asset's value.